Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) and cyclophosphamide (CY). We studied the pharmacokinetics of cyclophosphamide on hemodialysis and compared clinical parameters including time to engraftment and toxicity with parameters of a patient with normal renal function who also received an unrelated marrow as treatment for CML in first chronic phase. Our results suggest that TBI/CY is a suitable conditioning regimen for allogeneic transplantation in patients with hematological malignancy and renal failure on hemodialysis. Keywords: bone marrow transplantation; renal failure; cyclophosphamide; total body irradiation; pharmacokinetics; hemodialysis Matched unrelated donor (MUD) transplantation is the best available treatment for young patients with CML in chronic or accelerated phase without a matched sibling donor.
Matched unrelated donor (MUD) transplantation is the best available treatment for young patients with CML in chronic or accelerated phase without a matched sibling donor. [1] [2] [3] However, a serious therapeutic problem for BMT is hemodialysis-dependent renal insufficiency. An important question in this clinical setting relates to the optimal conditioning regimen to ensure an adequate myelosuppression in patients with disturbed renal function on hemodialysis. There is concern with regard to the tolerance of intensive chemotherapy in hematological patients with severe renal failure. 4 The aim of our report is to show that a conditioning regimen with TBI and CY can be used successfully in a patient with CML and severe renal insufficiency requiring hemodialysis. 
Patients and methods
A 31-year-old patient with Ph+ CML (patient A) was treated with a combination of alpha-interferon and hydroxyurea for 5 years and with hydroxyurea alone for the last 6 months before admission to our department. A MUD transplantation was offered to the patient according to the recommendations of the Consensus Panel chaired by EC Gordon Smith stating that for patients with CML in chronic phase or accelerated phase, unrelated donor BMT should be considered as the best available treatment at present for patients without a matched sibling donor. 2 The patient developed malignant nephrosclerosis and was hemodialysis-dependent on admission. The data were compared to the data in a matched pair patient (patient B) with similar clinical characteristics conditioned with the same regimen ( Table 1 ). The conditioning regimen for BMT consisted of TBI with a total dose of 13.5 Gy from days Ϫ6 to Ϫ4 and CY 60 mg/kg once daily i.v. on days Ϫ3 and Ϫ2 (total dose 120 mg/kg).
CY concentration was determined in serum and dialysate of patient A, and in serum and urine of patient B. Hemodialysis was performed in patient A 6 h after each CY infusion over a period of 6 h on days Ϫ3 and Ϫ2. The patient received, in addition, a bladder irrigation, 5 and a continuous i.v. infusion of mesna 60 mg/kg body weight/24 h on days Ϫ3 and Ϫ2. Patient B received an i.v. infusion of mesna 100 mg/kg body weight/24 h and hydration with 3.0 l/m 2 /day. GVHD prophylaxis consisted of CsA 5 mg/kg starting on day Ϫ3, as continuous infusion in patient A, and prednisolone at a dosage of 0.5 mg/kg from day +7. GVHD prophylaxis by using short-term methotrexate (MTX) was omitted in patient A due to clearance by hemodialysis. 
Results
Drug-related toxicity 9 using TBI and high-dose CY was similar in both patients. Patient A and patient B both developed grade II mucositis, grade II gastrointestinal toxicity and only mild hepatic dysfunction. Systemic administration of mesna, forced diuresis, and continuous bladder irrigation prevented hemorrhagic cystitis after high-dose CY in patient A.
The CY concentrations measured as outlined in both patients reached the expected values for high-dose therapy. 10 Decreases in CY concentrations and in half-lives were observed in both patients during the second day of treatment (Table 2 and Figure 1 ) as expected. [11] [12] [13] [14] CY concentrations in all samples of the dialysate of patient A were below 20 mol/l. Peak concentrations were reached in the urinary samples of patient B 4 h after CY infusion, ie 2407.4 mol/l on day Ϫ3 and subsequently 2185.8 mol/l on day Ϫ2. Acute GVHD was not observed in either patient. No difference was seen regarding the time of engraftment (Table 1 ).
Discussion
We demonstrate that a preparative regimen consisting of TBI and high-dose CY is feasible in patients with hematological malignancies and renal failure. Drug-related toxicity and pharmacokinetics of CY in the patient requiring dialysis were similar to the patient with normal renal function. CY is hydroxylated by the hepatic microsomal P-450 system to 4-hydroperoxycyclophosphamide (4-HC). 4-HC is transported to peripheral tissues, where it is converted intracellularly to aldophosphamide and to the final active metabolites, acrolein and phosphoramide mustard. 7 The main CY clearance is hepatic by conversion to inactive metabolites. 11 The renal clearance of CY and its metabolites is low. The lower values of CY concentrations and the half-lives on the second day of treatment are due to the self-induction of CY metabolism as already described. [12] [13] [14] [15] In conclusion, hemodialysis might be useful in removing metabolites of cyclophosphamide in patients with renal dysfunction receiving high-dose chemotherapy. 16 This report indicates that patients with severe renal failure may receive intensive myeloablative therapy with unrelated BMT without major adverse clinical events.
